Company Profile

Notal Vision™ was founded in 2000 by medical professionals from Israel's leading medical centers. The Company has assembled a team of ophthalmologists that have AMD expertise and business experience, R&D specialists, engineers, software engineers, business developers and researchers. Currently, there are 32 full-time employees, of them 3 MDs and 4 PhDs. In addition, Notal has recruited a scientific advisory board that includes leading retinal specialists from around the world.

Notal Vision enjoys broad financial backing and dedicates more technical resources than any other company in the field of diagnostics for the early detection of AMD. The company is headquartered in Tel Aviv, Israel.

The company is developing the first comprehensive diagnostic solutions for the early detection and monitoring of Age-Related Macular Degeneration (AMD), the leading cause of blindness in the world today.

To address the growing need for early detection of wet AMD and for the continuous monitoring of patients with dry AMD, Notal Vision™ has developed the patented Preferential Hyperacuity Perimetery - Foresee PHP™ platform, designed to detect and monitor the progression of the disease in a non-invasive manner.
Since its launch in 2004, the PHP has been sold to eye care professionals in the US and has gained a reputation as an outstanding tool for the detection of the conversion of dry to wet AMD.

Foresee PHP is the second-generation PHP, now sold in the US through MSS (www.ms-services.com) and worldwide through a chain of distributors. Foresee PHP features an automated diagnostic exam and tracking of changes in the visual field over time.